5th STING And TLR-Targeted Therapies Summit 2024

The innate immune system is increasingly being recognised as a target for a range of exciting applications with high unmet need, from those difficult to treat cancers to infectious and inflammatory disease.

The past year has seen a mix of ups and downs for this space, with several companies entering the clinic, emerging new modalities of STING/TLR agonists and on the other side some clinical setbacks.

The 5th Annual STING and TLR Targeted Therapies Summit returns at a crucial time to unpick the lessons of the past year and finally unleash the well-recognised potential of innate immunotherapy.

In this dynamic field which continuously sees new approaches, keep track of all the goings on within industry, learn the best approach for selecting the right patient population and how to strike that ever tricky balance of safety and efficacy.

This meeting covers everything from early discovery to clinical trial rationale across the innate immune pathway including TLR, STING and broader innate immune system targets like PTPN2/PTPN1 and RNA modifying enzymes, alongside evaluating the rationale for combination approaches with checkpoint inhibitors and beyond.

This meeting will once again converge the key players in STING/TLR and beyond, with actionable insights to unlock the potential of harnessing the innate immune system to meet unmet needs.

URLs:

Tickets: https://go.evvnt.com/2277808-2?pid=91

Brochure: https://go.evvnt.com/2277808-3?pid=91

Prices:

Conference + 2 Workshops - Drug Developer: USD 4197.00,

Conference + 1 Workshop - Drug Developer: USD 3598.00,

Conference Only - Drug Developer: USD 2999.00,

Conference + 2 Workshops - Solution Provider: USD 5097.00,

Conference + 1 Workshop - Solution Provider: USD 4398.00,

Conference Only - Solution Provider: USD 3699.00,

Conference + 2 Workshops - Academic: USD 3597.00,

Conference + 1 Workshop - Academic: USD 3098.00,

Conference Only - Academic: USD 2599.00

Speakers: Aarron Willingham, Executive Director, Merck and Co, Anna Galkin, CSO, Axelia Oncology, Dae-Shik Kim Sr., Principal Scientist, Eisai, Dimple Modi, Director - Precision Medicine, Regeneron, Dinesh Chandra, Associate Director, Interventional Oncology, Johnson and Johnson, Diwakar Davar, Associate Professor and Director - Melanoma Clinical and Skin Cancer Program, University of Pittsburgh Medical Center, Elena Bekerman, Senior Scientist - Research and Virology, Gilead Sciences, James Appleman, Co- Founder, Chief Scientific Officer, Senior Vice- President and Director - Research and Development, Primmune Therapeutics, Inc., Kathleen McGuire, Principal Research Scientist, Abbvie, Kevin Heller, Chief Medical Officer, Tallac Therapeutics, Lei Jin, Associate Professor (tenured), University of Florida, Maddie Olson, Clinical Scientist, OncoNano Medicine Inc., Michael Newman, Founder and Chief Scientific Officer, Indaptus Therapeutics, Paul Song, Chief Scientific Officer, Genequantum Healthcare, Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics, Scott Pesiridis, Scientific Director and GSK Fellow, GlaxoSmithKline Plc, Steven Katz, Chief Medical Officer, TriSalus Life Sciences, Tony Zhang, Co-founder and CEO, Tyligand, Yaara Ofir-Rosenfeld Director, Translational Oncology, STORM Therapeutics Ltd., Zer En Peng, Research Analyst, Beacon